{"nctId":"NCT00427921","briefTitle":"Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)","startDateStruct":{"date":"2007-01"},"conditions":["Crohn's Disease"],"count":304,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: adalimumab"]}],"interventions":[{"name":"adalimumab","otherNames":["ABT-D2E7","Humira"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males or females 18 years of age and older\n* Females: Not of childbearing potential OR Practicing approved birth control throughout the study and for 150 days after study completion\n* Diagnosis of moderate to severe CD for greater than 16 weeks prior to screening; Crohn's Disease Activity Index score \\> 220 OR Harvey Bradshaw Index equal to or higher than 7, and who are refractory to optimal conventional therapies such as, 5-aminosalicylic acid (5-ASA), glucocorticoids, and immunosuppressive therapies (azathioprine, 6-MP and MTX)\n* Subjects who failed prior infliximab therapy (as determined by the primary investigator), including those who never clinically responded (\"primary non-responders\")\n\nExclusion Criteria:\n\n* History of cancer other than some skin and cervical cancers\n* History of opportunistic infections, central nervous system (CNS) demyelinating disease, chronic viral hepatitis, or untreated tuberculosis\n* Subjects with other, poorly controlled medical conditions\n* Subjects with any prior exposure to TysabriÂ® (natalizumab)\n* Subjects who have received any investigational agent in the past 30 days or 5 half-lives prior to screening (whichever is longer)\n* Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Extent of Exposure - Duration in Days","description":"Extent of exposure for all adalimumab treated subjects","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"159.2","spread":"34.78"}]}]}]},{"type":"POST_HOC","title":"Harvey-Bradshaw Index (HBI) Mean Change From Baseline","description":"HBI score (range 0-30) sum subtotal of 5 parameters of subject's CD activity: a)Well being 0=very well-4=terrible b) Abdominal pain 0=none- 3=severe c) Number liquid stools per day d) Abdominal mass 0=none-3=tender e) Complications: 1 point each. Decrease indicates improvement. Absolute decrease of 3 units on scale is clinically important.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.53","spread":"5.175"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.32","spread":"5.008"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.36","spread":"5.031"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.92","spread":"5.162"}]}]}]},{"type":"SECONDARY","title":"Fistula Count Mean Change From Baseline (Change in Number of Fistulas From Baseline).","description":"Draining fistula counts is the sum of abdominal and perianal fistulas for each subject at each visit.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"0.644"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"0.587"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"0.567"}]}]}]},{"type":"PRIMARY","title":"Total Number of Injections of Adalimumab","description":"Extent of exposure for all adalimumab treated subjects","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":"4.24"}]}]}]},{"type":"PRIMARY","title":"Compliance With Number of Injections of Adalimumab. Compliance Corresponds to Patients Who Received Their Injections.","description":"Treatment compliance (%) = 100 \\* (Number of doses of study medication actually received)/(Number of doses planned during the subject's participation in the study).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.85","spread":"4.207"}]}]}]},{"type":"POST_HOC","title":"Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Mean Change From Baseline","description":"Quality of life questionnaire for patients with IBD consisting of 4 domains: systemic, social, emotional, and bowel. This is a 10-item questionnaire, and all items are reported with a 7-point scale (ranging from 1 = poor HRQOL, to 7 = optimum HRQOL). Total SIBDQ score ranges from 10 (quality of life has been negatively affected tremendously by IBD) to 70 (quality of life is barely impacted by IBD). A change greater than 9 points was the minimal clinically important difference (MCID).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.16","spread":"10.692"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.85","spread":"11.591"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.14","spread":"11.783"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.06","spread":"12.209"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.74","spread":"12.629"}]}]}]},{"type":"SECONDARY","title":"Overall Health Care Resource Utilization","description":"From the \"Overall Health Care Resource Utilization Questionnaire\": Number visits to physician, number visits to Emergency Room, number of hospital admissions, number of days of hospitalization.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.13","spread":"2.794"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"0.522"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.346"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"2.790"}]}]}]},{"type":"SECONDARY","title":"Employment Status: Number of Subjects Employed","description":"Summary of employment status of those employed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"195","spread":"64.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"199","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"198","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"208","spread":null}]}]}]},{"type":"SECONDARY","title":"50% Improvement in Draining Fistula Count and Fistula Healing","description":"Decrease in draining fistula is beneficial. \"50 percent improvement\" refers to a reduction in the number of baseline fistula by 50 percent.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Work Productivity and Activity Impairment - Change From Baseline in Overall Work Impairment","description":"Scores are expressed as impairment percentages, higher numbers indicate greater impairment and less productivity (0% = no impairment; 100% = total loss of work productivity).\n\nMinimal clinically important difference = 7 points. Measure is Mean percent change.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.08","spread":"28.454"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.36","spread":"29.337"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.93","spread":"33.669"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.23","spread":"30.403"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.49","spread":"32.286"}]}]}]},{"type":"SECONDARY","title":"Hematology - Change From Baseline to Final Visit","description":"Changes from the Group mean at baseline are compared to the final visit Group mean value","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"12.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.011","spread":"0.0376"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.353"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.2","spread":"89.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.59","spread":"3.297"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.005","spread":"3.1777"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.408","spread":"0.7285"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.014","spread":"0.1725"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.009","spread":"0.1505"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.015","spread":"0.0617"}]}]}]},{"type":"SECONDARY","title":"Clinical Chemistry - Change From Baseline to Final Visit","description":"Changes from the Group mean at Baseline are compared to the final visit Group mean value","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"17.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"10.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.2","spread":"21.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"4.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"10.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"1.367"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"52.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.016","spread":"0.2588"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.008","spread":"0.1189"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.00","spread":"0.779"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"4.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"4.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.021","spread":"0.7024"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.093","spread":"0.7581"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.181","spread":"28.7023"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.268","spread":"1.3893"}]}]}]},{"type":"SECONDARY","title":"Urinalysis - Change From Baseline to Final Visit","description":"Changes from the Group mean at baseline are compared to the final visit Group mean value","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.980"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0004","spread":"0.00713"}]}]}]},{"type":"SECONDARY","title":"Work Productivity and Activity Impairment - Change From Baseline in Absenteeism","description":"The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.99","spread":"24.592"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.55","spread":"27.543"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.74","spread":"33.477"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.54","spread":"27.260"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.46","spread":"29.167"}]}]}]},{"type":"SECONDARY","title":"Work Productivity and Activity Impairment - Change From Baseline in Presenteeism","description":"The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.58","spread":"26.115"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.94","spread":"27.151"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.79","spread":"30.113"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.96","spread":"28.472"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.69","spread":"30.058"}]}]}]},{"type":"SECONDARY","title":"Work Productivity and Activity Impairment - Change From Baseline in Activity Impairment","description":"The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated, self-administered tool used to assess the impact of disease on productivity. There are four component scores for WPAI: absenteeism, presenteeism, total work productivity impairment, daily activity impairment. The score for each component ranges from 0% to 100% (0%=no impairment; 100%=total loss of work productivity or activity). The minimal clinically important difference (MCID) is an absolute change of 7%.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.59","spread":"26.928"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.79","spread":"28.431"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.36","spread":"28.697"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.00","spread":"29.552"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.98","spread":"30.484"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":44},"commonTop":["Crohn's Disease","Abdominal pain","Injection site reaction","Nausea","Headache"]}}}